TABLE 1.
Patient Characteristics
| Characteristic | All (N = 120) |
|---|---|
| Median age, years (range) | 59 (20-82) |
| Sex, No. (%) | |
| Male | 97 (80.8) |
| Female | 23 (19.2) |
| Race, No. (%) | |
| White | 103 (85.8) |
| Black or African American | 11 (9.2) |
| Asian | 5 (4.2) |
| Other | 1 (0.8) |
| Karnofsky performance status, %, No. (%) | |
| 100 | 15 (12.5) |
| 90 | 63 (52.5) |
| 80 | 32 (26.7) |
| 70 | 10 (8.3) |
| Smoking history, No. (%) | |
| Current | 10 (8.3) |
| Previous | 61 (50.9) |
| Never | 49 (40.8) |
| Cohorts, No. (%) | |
| Phase I | 54 (45) |
| Urothelial carcinoma | 24 (20) |
| RCC | 12 (10) |
| Adenocarcinoma of bladder | 10 (8.3) |
| Rare GU tumors treated | 12 (10) |
| Penile carcinoma treated | 8 (6.7) |
| Type of tumor, No. (%) | |
| Urothelial carcinoma | 39 (32.5) |
| Clear cell RCCa | 16 (13.3) |
| Adenocarcinoma bladder/urachal | 15 (12.5) |
| Penile carcinoma | 11 (9.2) |
| Prostate adenocarcinoma | 10 (8.3) |
| Squamous cell carcinoma bladder | 8 (6.7) |
| Germ cell tumor | 6 (5.0) |
| Small cell carcinoma of bladder/renal pelvis | 4 (3.3) |
| Renal medullary carcinoma | 3 (2.5) |
| Testicular primitive neuroectodermal tumor | 2 (1.7) |
| Trophoblastic tumor | 1 (0.83) |
| Sertoli cell tumor | 1 (0.83) |
| Collecting duct carcinoma | 1 (0.83) |
| Chromophobe RCC | 1 (0.83) |
| Papillary RCC | 1 (0.83) |
| Sarcomatoid bladder | 1 (0.83) |
| Metastasis location, No. (%) | |
| Lymph node only | 15 (12.5) |
| Bone | 19 (15.8) |
| Visceral disease | 80 (66.7) |
| Liver | 37 (30.8) |
| Lung | 54 (45.0) |
| Median number of previous treatments (range) | 1 (0-8) |
| No. of previous treatments, No. (%) | |
| 0 | 21 (17.5) |
| 1 | 54 (45.0) |
| 2 | 22 (18.3) |
| ≥3 | 23 (19.2) |
Abbreviations: CaboNivo, cabozantinib + nivolumab; CaboNivoIpi, cabozantinib + nivolumab + ipilimumab; GU, genitourinary; RCC, renal cell carcinoma.
a
Three patients with clear cell RCC had >50% sarcomatoid features.